propranolol has been researched along with su 11248 in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Boix, E; Herrero, J; Meana, JA; PiƱar, D | 1 |
Deng, GH; Jiang, Y; Liu, J; Peng, XC; Wang, Y; Wei, YQ; Zhang, J | 1 |
1 review(s) available for propranolol and su 11248
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for propranolol and su 11248
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Sunitinib-induced thyrotoxicosis.
Topics: Aged; Antineoplastic Agents; Carbimazole; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Prednisone; Propranolol; Pyrroles; Sunitinib; Thyroid Hormones; Thyrotoxicosis | 2009 |
Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model.
Topics: Adrenergic alpha-Agonists; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Indoles; Inhibitory Concentration 50; Interleukin-6; Interleukin-8; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Norepinephrine; Propranolol; Pyrroles; Receptors, Adrenergic, beta; Signal Transduction; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor A | 2014 |